The anti-malarial drug atovaquone potentiates platinum-mediated cancer cell death by increasing oxidative stress
Platinum chemotherapies are highly effective cytotoxic agents but often induce resistance when used as monotherapies. Combinatorial strategies limit this risk and provide effective treatment options for many cancers. Here, we repurpose atovaquone (ATQ), a well-tolerated & FDA-approved anti-malar...
Hoofdauteurs: | Coates, JTT, Rodriguez-Berriguete, G, Puliyadi, R, Ashton, T, Prevo, R, Wing, A, Granata, G, Pirovano, G, McKenna, GW, Higgins, GS |
---|---|
Formaat: | Journal article |
Taal: | English |
Gepubliceerd in: |
Springer Nature
2020
|
Onderwerpen: |
Gelijkaardige items
-
The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia
door: Ashton, T, et al.
Gepubliceerd in: (2016) -
The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia
door: Thomas M. Ashton, et al.
Gepubliceerd in: (2016-07-01) -
CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner
door: Prevo, R, et al.
Gepubliceerd in: (2018) -
Investigating the role of the anti-malarial drug Atovaquone in anti-cancer therapy
door: Watson, D, et al.
Gepubliceerd in: (2019) -
Antitumour effect of the mitochondrial complex III inhibitor Atovaquone in combination with anti-PD-L1 therapy in mouse cancer models
door: Gonzalo Rodriguez-Berriguete, et al.
Gepubliceerd in: (2024-01-01)